期刊
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
卷 11, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s40164-022-00291-0
关键词
T cell receptor; TCR-T cells; Cellular immunotherapy; Solid tumors
资金
- Guangdong Basic and Applied Basic Research Foundation [2021A1515110004]
- China postdoctoral science foundation [2021M701427]
This article summarizes the current advances in TCR-T cell therapy and their potential advantages for solid tumor immunotherapy.
T cell immunotherapy remains an attractive approach for cancer immunotherapy. T cell immunotherapy mainly employs chimeric antigen receptor (CAR)- and T cell receptor (TCR)-engineered T cells. CAR-T cell therapy has been an essential breakthrough in treating hematological malignancies. TCR-T cells can recognize antigens expressed both on cell surfaces and in intracellular compartments. Although TCR-T cells have not been approved for clinical application, a number of clinical trials have been performed, particularly for solid tumors. In this article, we summarized current TCR-T cell advances and their potential advantages for solid tumor immunotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据